In development: Guidance, quality standards and advice

Skip to filters Skip to results

Showing 1 to 10 of 23

Sort by

Keyword or reference number: PembrolizumabRemove Keyword or reference number: Pembrolizumab filter

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Belzutifan with pembrolizumab for adjuvant treatment of clear cell renal cell carcinoma after nephrectomy [ID6645]	Technology appraisal guidance	TBC
Enfortumab vedotin with pembrolizumab for neoadjuvant and adjuvant treatment of muscle-invasive bladder cancer when cisplatin is unsuitable [ID6607]	Technology appraisal guidance	TBC
Favezelimab–pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after anti-PD-L1 treatment [ID6393]	Technology appraisal guidance	TBC
Niraparib with pembrolizumab for maintenance treatment of advanced non-small-cell lung cancer after platinum-based chemotherapy with pembrolizumab [ID6345]	Technology appraisal guidance	TBC
Pembrolizumab adjuvant for urothelial carcinoma and/or localised muscle invasive bladder cancer [TSID12021]	Technology appraisal guidance	TBC
Pembrolizumab before surgery (neoadjuvant) then with radiotherapy after surgery (adjuvant) for newly diagnosed, resectable, locally advanced, squamous cell head and neck cancer [ID6477]	Technology appraisal guidance	TBC
Pembrolizumab for adjuvant treatment of hepatocellular carcinoma [ID3994]	Technology appraisal guidance	29 October 2026
Pembrolizumab for adjuvant treatment of locally advanced cutaneous squamous cell carcinoma after surgery and radiotherapy ID 6473	Technology appraisal guidance	TBC
Pembrolizumab with chemoradiation, then with or without olaparib, for untreated unresectable locally advanced non-small-cell lung cancer [ID6399]	Technology appraisal guidance	TBC
Pembrolizumab with chemotherapy for adjuvant treatment of newly diagnosed high-risk endometrial cancer after surgery with curative intent [ID6207]	Technology appraisal guidance	TBC

Results per page

10
25
50
All